Mochi Health Lowers GLP-1 Medication Prices and Introduces Integrated Lab Testing for Weight Loss Patients
Mochi Health, a telehealth provider, has reduced the cost of its compounded GLP-1 medications, semaglutide and tirzepatide, and launched a new integrated lab-testing service called Mochi Labs. The new dose-based pricing structure means compounded semaglutide now starts at $60 per month and compounded tirzepatide at $90 per month, with no dose costing more than previous rates. Mochi Labs allows patients to order and manage bloodwork, including cholesterol, hemoglobin A1C, thyroid screening, and comprehensive metabolic testing, directly through the platform. This service aims to help patients track key health markers and allow providers to adjust treatment as needed. The lab service is available in most U.S. states, excluding New York, New Jersey, Rhode Island, and Hawaii.